← Leaderboards
Andrea Jenay Ruff
Johns Hopkins University
$102,510,867
Attributed
$102,510,867
Total exposure
17
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $18.3M · FY2005–17$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
CDC$76,504,708 · 1
NIH$26,006,159 · 16
By mechanism
U2G$76,504,708 · 1
U01$19,721,432 · 2
R01$5,478,923 · 2
D43$803,740 · 1
M01$2,064 · 11
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Arun Venkatesan$2,498,274
- Michael Edward Zwick$10,806,976
- Robert H Gilman$35,342,766
- Gyanu Lamichhane$9,492,958
- Ronald S Brookmeyer$3,503,229
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHiv InfectionsPediatric AidsClinical ResearchAids TherapyHuman Therapy EvaluationClinical Trial Phase IChild (0-11)Combination ChemotherapyAdolescence (12-20)Infant Human (0-1 Year)Antiaids AgentPediatric PharmacologyAids Education /PreventionVertical TransmissionHuman Pregnant SubjectNevirapineDrug Screening /EvaluationPharmacokineticsPathologic ProcessZidovudineOpportunistic InfectionsLongitudinal Human StudyOutcomes Research
Grant awards (65)
Optimizing HIV Prevention in Ethiopia through Implementation Science$1
D43 · FY2017 · TW · contact PI
Optimizing HIV Prevention in Ethiopia through Implementation Science$168,070
D43 · FY2016 · TW · contact PI
Optimizing HIV Prevention in Ethiopia through Implementation Science$100,000
D43 · FY2015 · TW · contact PI
Optimizing HIV Prevention in Ethiopia through Implementation Science$267,594
D43 · FY2014 · TW · contact PI
TECHNICAL SUPPORT IN HIV TREATMENT, CARE AND PREVENTION IN ETHIOPIA$5,131,906
U2G · FY2013 · PS · contact PI
Novel techniques for the detection of Pediatric TB in Ethiopia$414,164
R01 · FY2013 · HD · contact PI
Optimizing HIV Prevention in Ethiopia through Implementation Science$268,075
D43 · FY2013 · TW · contact PI
TECHNICAL SUPPORT IN HIV TREATMENT, CARE AND PREVENTION IN ETHIOPIA$7,401,896
U2G · FY2012 · PS · contact PI
TECHNICAL SUPPORT IN HIV TREATMENT, CARE AND PREVENTION IN ETHIOPIA$6,341,470
U2G · FY2012 · PS · contact PI
TECHNICAL SUPPORT IN HIV TREATMENT, CARE AND PREVENTION IN ETHIOPIA$4,748,598
U2G · FY2011 · PS · contact PI
Novel techniques for the detection of Pediatric TB in Ethiopia$436,945
R01 · FY2011 · HD · contact PI
TECHNICAL SUPPORT IN HIV TREATMENT, CARE AND PREVENTION IN ETHIOPIA$13,641,216
U2G · FY2010 · PS · contact PI
TECHNICAL SUPPORT IN HIV TREATMENT, CARE AND PREVENTION IN ETHIOPIA$18,274,186
U2G · FY2009 · PS · contact PI
TECHNICAL SUPPORT IN HIV TREATMENT, CARE AND PREVENTION IN ETHIOPIA$12,980,436
U2G · FY2008 · PS · contact PI
TECHNICAL SUPPORT IN HIV TREATMENT, CARE AND PREVENTION IN ETHIOPIA$7,985,000
U2G · FY2007 · PS · contact PI
ZDV USE TO PREVENT MATERNAL/INFANT HIV TRANSMISSION$738,003
U01 · FY2007 · AI · contact PI
ZDV USE TO PREVENT MATERNAL/INFANT HIV TRANSMISSION$100,000
U01 · FY2007 · AI · contact PI
ZDV USE TO PREVENT MATERNAL/INFANT HIV TRANSMISSION$4,525,000
U01 · FY2006 · AI · contact PI
ZDV USE TO PREVENT MATERNAL/INFANT HIV TRANSMISSION$3,534,704
U01 · FY2006 · AI · contact PI
ZDV USE TO PREVENT MATERNAL/INFANT HIV TRANSMISSION$1,300,000
U01 · FY2006 · AI · contact PI
ACTG 265$527
M01 · FY2006 · RR · contact PI
ZDV USE TO PREVENT MATERNAL/INFANT HIV TRANSMISSION$4,800,000
U01 · FY2005 · AI
ZDV USE TO PREVENT MATERNAL/INFANT HIV TRANSMISSION$883,905
R01 · FY2005 · AI
Baltimore Pediatric AIDS Clinical Trials Group$726,766
U01 · FY2005 · AI
ZDV USE TO PREVENT MATERNAL/INFANT HIV TRANSMISSION$600,000
R01 · FY2005 · AI
ZDV USE TO PREVENT MATERNAL/INFANT HIV TRANSMISSION$271,035
U01 · FY2005 · AI
ACTG 265$715
M01 · FY2005 · RR
ZDV USE TO PREVENT MATERNAL/INFANT HIV TRANSMISSION$1,424,827
R01 · FY2004 · AI
Baltimore Pediatric AIDS Clinical Trials Group$686,965
U01 · FY2004 · AI
ZDV USE TO PREVENT MATERNAL/INFANT HIV TRANSMISSION$648,907
R01 · FY2004 · AI
ZDV USE TO PREVENT MATERNAL/INFANT HIV TRANSMISSION$300,000
R01 · FY2004 · AI
ACTG 265$822
M01 · FY2004 · RR
Baltimore Pediatric AIDS Clinical Trials Group$742,005
U01 · FY2003 · AI
Baltimore Pediatric AIDS Clinical Trials Group$47,196
U01 · FY2003 · AI
Baltimore Pediatric AIDS Clinical Trials Group$727,739
U01 · FY2002 · AI
ACTG 397--SAQUINAVIR COMBINATION THERAPIES IN HIV CHILD$0
M01 · FY2002 · RR
TRIAL OF AT/AZ VS TMP/SMX IN BACTERIAL INFECTIONS--HIV$0
M01 · FY2002 · RR
ACTG: 366 RAD 1: PHASE I &II ANTIRETROVIRAL MGN ALGORITHM$0
M01 · FY2002 · RR
PH I &II MULTICENTER COMPARE FOUR ANTIRETROVIRAL REGIMENS ACTG 377$0
M01 · FY2002 · RR
ACTG 356 EARLY INTENSIVE ANITRETROVIRAL COMBINATION THERAPY IN HIV 1 CHILDREN$0
M01 · FY2002 · RR
MULTICENTER TRIAL--EFFECT OF CONCENTRATED INFANT FORMULA ON HIV+ INFANT GROWTH$0
M01 · FY2002 · RR
PEDIATRIC LATE OUTCOME PROTOCOL 219$0
M01 · FY2002 · RR
PREVENTION OF SERIOUS BACTERIAL IN HIV CHILDREN$0
M01 · FY2002 · RR
ACTG 230--PHASE I STUDY--HIV-1 ENVELOPE ANTIGEN/CHILDREN BORN TO HIV MOTHERS$0
M01 · FY2002 · RR
BALTIMORE PEDIATRIC AIDS CLINICAL TRIALS GROUP$767,645
U01 · FY2001 · AI
PREVENTION OF SERIOUS BACTERIAL IN HIV CHILDREN$0
M01 · FY2001 · RR
ACTG 397--SAQUINAVIR COMBINATION THERAPIES IN HIV CHILD$0
M01 · FY2001 · RR
TRIAL OF AT/AZ VS TMP/SMX IN BACTERIAL INFECTIONS--HIV$0
M01 · FY2001 · RR
ACTG: 366 RAD 1: PHASE I &II ANTIRETROVIRAL MGN ALGORITHM$0
M01 · FY2001 · RR
PH I &II MULTICENTER COMPARE FOUR ANTIRETROVIRAL REGIMENS ACTG 377$0
M01 · FY2001 · RR
ACTG 356 EARLY INTENSIVE ANITRETROVIRAL COMBINATION THERAPY IN HIV 1 CHILDREN$0
M01 · FY2001 · RR
MULTICENTER TRIAL--EFFECT OF CONCENTRATED INFANT FORMULA ON HIV+ INFANT GROWTH$0
M01 · FY2001 · RR
PEDIATRIC LATE OUTCOME PROTOCOL 219$0
M01 · FY2001 · RR
ACTG 230--PHASE I STUDY--HIV-1 ENVELOPE ANTIGEN/CHILDREN BORN TO HIV MOTHERS$0
M01 · FY2001 · RR
ZDV USE TO PREVENT MATERNAL/INFANT HIV TRANSMISSION$770,175
R01 · FY2000 · AI
BALTIMORE PEDIATRIC AIDS CLINICAL TRIALS GROUP$754,374
U01 · FY2000 · AI
ACTG 230--PHASE I STUDY--HIV-1 ENVELOPE ANTIGEN/CHILDREN BORN TO HIV MOTHERS$0
M01 · FY2000 · RR
TRIAL OF AT/AZ VS TMP/SMX IN BACTERIAL INFECTIONS--HIV$0
M01 · FY2000 · RR
ACTG: 366 RAD 1: PHASE I &II ANTIRETROVIRAL MGN ALGORITHM$0
M01 · FY2000 · RR
PH I &II MULTICENTER COMPARE FOUR ANTIRETROVIRAL REGIMENS ACTG 377$0
M01 · FY2000 · RR
ACTG 356 EARLY INTENSIVE ANITRETROVIRAL COMBINATION THERAPY IN HIV 1 CHILDREN$0
M01 · FY2000 · RR
MULTICENTER TRIAL--EFFECT OF CONCENTRATED INFANT FORMULA ON HIV+ INFANT GROWTH$0
M01 · FY2000 · RR
PEDIATRIC LATE OUTCOME PROTOCOL 219$0
M01 · FY2000 · RR
PREVENTION OF SERIOUS BACTERIAL IN HIV CHILDREN$0
M01 · FY2000 · RR
ACTG 397--SAQUINAVIR COMBINATION THERAPIES IN HIV CHILD$0
M01 · FY2000 · RR